Competing interests: The authors declare no competing financial interests in direct relation to the work reported. The following authors also declare no competing financial interests otherwise: PJH, KGR, SRH, JFL, RP, RJB, SMS, MT, CAH, MS, CJZM, DLV, EB, SLS, RBK, TGC. In the interest of transparency, additional potential conflicts of interest for the remaining authors are included below. TH: Consultancy for BeiGene. Research funding provided to the institution from BeiGene. YW: Membership on Board of Directors or advisory committees for Incyte, InnoCare, LOXO Oncology, Eli Lilly, TG Therapeutics, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie (compensation to institution). Research funding (to institution) from Incyte, InnoCare, LOXO Oncology, Eli Lilly, Novartis, Genentech, MorphoSys, GenMab, AbbVie. Honorarium (to institution) from Kite. SSK: Patents and royalties from Novartis, Humanigen, Mettafforgr, Sendero, and MustangBio; Research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen; Scientific advisory boards in Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, and Novartis; DSMB: Humanigen, Carisma; Consultancy: Torque, Calibr, Novartis, Capstan Bio, and Humanigen. EM: Honorarium from Janssen. Consultation fee from Protego (paid to the institution). SA: Consultancy for BMS, Janssen, Amgen, Pharmacyclics, GSK, Takeda, Genentech, AbbVie, Karyopharm, Beigene, Sanofi. Research funding from BMS, Janssen, Amgen, Pharmacyclics, Ascentage, Medimmune, Cellectar, Xencor, GSK. ABK: Membership on Board of Directors or advisory committees for AbbVie and TG Therapeutics. TDS: Research funding from Abbvie, Genentech, and Pharmacyclics. NEK: Membership on Board of Directors or advisory committees for Abbvie, BMS, Celgene, Pharmacyclics, AstraZeneca, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Targeted Oncology, Agios Pharm, Morpho-sys, Rigel. Research funding from Abbvie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. WD: Employment with BeiGene. Research funding has been provided to the institution from Merck and DTRM. Participation in advisory board meetings for Merck and Octapharma. SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, Ascentage Pharma, Eli Lilly, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings.